Search results for " Systemic"
showing 10 items of 201 documents
Gingivitis
2018
Gingival inflammation is caused by bacterial plaque (dental biofilm) that accumulates daily on the teeth.Results in redness, slight swelling, or "puffiness" of the gums and bleeding on tooth brushing. Treatment involves thorough professional tooth cleaning and effective daily removal of dental plaque by tooth brushing and cleaning between the teeth. Necrotising ulcerative gingivitis (NUG) is a more serious condition that is mainly found in developing countries associated with people with severe malnutrition or HIV/AIDS with low CD4 T-cell counts.
Gingivitis
2016
Gingival inflammation is caused by bacterial plaque (dental biofilm) that accumulates daily on the teeth. Results in redness, slight swelling, or "puffiness" of the gums and bleeding on tooth brushing. Treatment involves thorough professional tooth cleaning and effective daily removal of dental plaque by tooth brushing and cleaning between the teeth. Necrotizing ulcerative gingivitis (NUG) is a more serious condition that is mainly found in developing countries associated with people with severe malnutrition or HIV/AIDS with low CD4 T-cell counts.
Periodontal disease and systemic diseases: interrelationships and interactions
2011
The focal infection theory, which for almost half a century justified indiscriminate extraction of teeth to cure focal infections, since the end of the 1940s has become progressively a discarded concept. In parallel with the declining importance assigned to pulp and periapical infections in the pathogenesis of focal diseases, over the last decade there has been increasing interest in the possible relationship between periodontal infection and systemic diseases. Periodontal pathogens and their products, as well as inflammatory mediators produced in gingival tissue, might enter the bloodstream through ulcerated pocket epithelium, causing systemic effects (focal diseases). On the basis of this…
Anakinra drug retention rate and predictive factors of drug survival in systemic juvenile idiopathic arthritis and adult onset Still’s disease.
2019
Introduction: Only a few studies have reported the long-term efficacy of interleukin (IL)-1 inhibition in systemic juvenile idiopathic arthritis (sJIA) and adult onset Still’s disease (AOSD). We herein describe Anakinra (ANA) effectiveness expressed in terms of drug retention rate (DRR) and evaluate predictive factors of drug survival in sJIA and ASOD patients. Objectives: Examine the overall DRR of ANA in sJIA and AOSD patients. Explore the influence of biologic line of treatment, and the concomitant use of disease modifying anti-rheumatic drugs (cDMARDs) on DRR in the whole sample and stratified according to the disease thereafter; find eventual predictive factors associated with events l…
Canakinumab in systemic juvenile idiopathic arthritis: clinical inactive disease rate and safety in italian patients
2019
Introduction: Systemic juvenile idiopathic arthritis (sJIA) is a polygenic autoinflammatory disease. The pathophysiology is still unclear, it is now well known that innate immune mechanisms play a central role with overproduction of inflammatory cytokines. The increased knowledge on the role of these cytokines has provided a change in the natural history of the disease with the introduction of the targeted treatments. Remarkable results has been observed with canakinumab, an anti-interleukin-1β monoclonal antibody, in two clinical trials but little information are available in real life. Objectives: To evaluate clinical inactive disease rate and safety of canakinumab in Italian patients wit…
Inter-organizational relationships in agri-food sector: a bibliometric review and future directions
2022
PurposeThe current competitive system, complex and rapidly changing, knowledge represents one of the main strategic resources for organizations. Agri-food organizations, traditionally characterized by low-knowledge management (KM) practices, are facing several challenges that require new knowledge to improve performance and their ability to survive. Since agri-food organizations are low-propensity R&D, they are forced into a collaborative approach and the creation of inter-organizational relationships (IORs) for knowledge transfer. The purpose of this study is to offer an overview of the academic literature on knowledge transfer within scientific institutions and agri-food organizations…
Outcomes of hepatocellular carcinoma patients treated with sorafenib: a meta-analysis of Phase III trials
2019
Aim: To benchmark overall survival (OS) and time to radiological progression (TTP) of patients enrolled in randomized controlled trials (RCTs) assessing sorafenib in advanced hepatocellular carcinoma using individual participant survival data, and to meta-analyze prognostic factors for OS and TTP. Methods: RCTs were identified through literature search until December 2018. Individual participant survival was reconstructed with an algorithm from published Kaplan–Meier curves. Results: Ten RCTs were included. Median OS was 10.0 months (95% CI: 9.6–10.5), and median TTP was 4.1 months (95% CI: 3.8–4.3). Multivariable analyses showed HCV positivity, absence of macrovascular invasion and extra-…
Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors and Applicability of First-Line Atezolizumab/Bevacizumab in a Real-Life Setti…
2021
Immune checkpoint inhibitors (ICIs) are the new frontier for the treatment of advanced hepatocellular carcinoma (HCC). Since the first trial with tremelimumab, a cytotoxic T-lymphocyte-associated protein 4 inhibitor, increasing evidence has confirmed that these drugs can significantly extend the survival of patients with advanced hepatocellular carcinoma (HCC). As a matter of fact, the overall survival and objective response rates reported in patients with advanced HCC treated with ICIs are the highest ever reported in the second-line setting and, most recently, the combination of the anti-programmed death ligand protein-1 atezolizumab with bevacizumab—an anti-vascular endothelial growth fa…
Psoriatic arthritis and COVID ‐19 pandemic: Consequences in medical treatment?
2020
The COVID‐19 pandemic has a strong negative impact on human society world‐wide. Patients with immune‐mediated disease may be prone to an increased risk of infection and/ or more severe course. We review the available data for patients with psoriatic arthritis (PSA) and systemic treatments. Current treatment options are summarized. Based upon the experience with COVID‐19 the following problems are addressed: (a) Can systemic treatment reduce comorbidities of PsA that are also comorbidities for COVID‐19? Does systemic medical treatment pose an increased risk of infection with SARS‐CoV‐2? Does systemic drug therapy have an impact on the risk of pulmonary fibrosis ‐ a factor with strong negativ…
The German COPD cohort COSYCONET: Aims, methods and descriptive analysis of the study population at baseline
2016
Abstract Background The German COPD cohort study COSYCONET (" CO PD and SY stemic consequences- CO morbidities NET work") investigates the interaction of lung disease, comorbidities and systemic inflammation. Recruitment took place from 2010 to 2013 in 31 study centers. In addition to the baseline visit, follow-up visits are scheduled at 6, 18, 36 and 54 months after baseline. The study also comprises a biobank, image bank, and includes health economic data. Here we describe the study design of COSYCONET and present baseline data of our COPD cohort. Methods Inclusion criteria were broad in order to cover a wide range of patterns of the disease. In each visit, patients undergo a large panel …